Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Elsayed Elsayed Wagih wikipedia , lookup
Hepatitis C wikipedia , lookup
Taura syndrome wikipedia , lookup
Human cytomegalovirus wikipedia , lookup
Canine distemper wikipedia , lookup
Orthohantavirus wikipedia , lookup
Influenza A virus wikipedia , lookup
Canine parvovirus wikipedia , lookup
Hepatitis B wikipedia , lookup
Marburg virus disease wikipedia , lookup
1 Synthetic Ebola glycoprotein for screening anti-Ebola entry inhibitors Ebola virus infection causes severe viral hemorrhagic fevers and has a mortality rate of up to 90%. There are five strains of Ebola virus. Each Ebola virus genome contains seven genes that encode eight viral proteins: glycoprotein (GP), sGP, NP, VP24, VP30, VP35, VP40, and RNA-dependent RNA polymerase (L). Ebola glycoprotein mediates viral entry into host cells. Virus entry is an essential component of the viral life cycle and an attractive target for therapy because inhibition of this step can block the propagation of virus at an early stage, minimizing the chance for the virus to evolve and acquire drug resistance. Thus, Ebola glycoprotein provides a target to design and screen for anti-Ebola entry inhibitors. UIC investigators have synthesized Ebola glycoprotein and Marburg glycoprotein expression constructs. Reference Number UIC-2015-047 Inventors Lijun Rong This glycoprotein expression vector can be used to generate pseudotype viruses that package Ebola-glycoprotein on the virion surface, which allows for screening of Ebola entry inhibitors. Campus Chicago Publications Currently there are no effective therapies or vaccines for Ebola virus. Discovery, synthesis, and biological evaluation of a novel group of selective inhibitors of filoviral entry – J Med Chem 2011 Anti-infective drug discovery for Ebola presents significant logistical and safety challenges due to the requirement for biosafety level 4 (BSL-4) containment and procedures. Identification of a smallmolecule entry inhibitor for filoviruses – J Virol 2011 Using synthetic Ebola glycoprotein to generate pseudotype viruses allows for the screening of anti-Ebola entry inhibitors in standard BSL -2 facilities. Contact information: David Klick Email: [email protected] Phone: 312-996-7779